Accounting for racial disparities, including in the quality of family history data, enhanced the predictive performance of a colorectal cancer (CRC) risk prediction model. The medical community is ...

Omitting race and ethnicity from colorectal cancer (CRC) recurrence risk prediction models could decrease their accuracy and fairness, particularly for minority groups, potentially leading to ...

Shield is the first and only blood test that has received full FDA approval as a primary screening option for CRC in average-risk adults aged 45 and older and can be ordered by any prescribing ...

Mayo Clinic researchers and NASA Frontier Development Lab scientists are working to fine-tune an artificial intelligence algorithm that detects spatio-temporal patterns related to colorectal cancer ...

Guardant Health has reported an encouraging clinical readout update on the performance of its latest algorithm for Shield ...